CXCL9 serum levels might be considered as a therapeutic marker for personalized treatment if CXCL9/CXCR3 blockade therapy is proved to be a useful adjunctive treatment for NPC in the future. The gene discussed is CXCR3; the disease is nasopharyngeal carcinoma.